SCHEDULE: OrbiMed Files Amendment to Schedule 13G for Forte Biosciences

OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Forte Biosciences, Inc. common stock.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Forte Biosciences, Inc. common stock by OrbiMed entities.
• The amendment, dated June 30, 2026, and filed on August 14, 2026, details the aggregate beneficial ownership of OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Capital LLC.
• OrbiMed Advisors LLC reports beneficial ownership of 1,264,980 shares, representing 6.2% of the class.
• OrbiMed Capital GP IX LLC reports beneficial ownership of 1,041,742 shares, representing 5.1% of the class.
• OrbiMed Capital LLC reports beneficial ownership of 312,725 shares, representing 1.5% of the class.
• The reporting persons collectively hold shares with shared voting and dispositive power, with OrbiMed Capital LLC holding sole voting and dispositive power over its reported shares.
• The filing confirms that the securities were not acquired for the purpose of influencing or changing the control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, with no significant new financial information or strategic shifts disclosed.

Positives

• The filing clarifies the beneficial ownership structure of OrbiMed entities concerning Forte Biosciences, Inc. stock.
• OrbiMed Capital LLC holds sole voting and dispositive power over its 312,725 shares (1.5%).

Negatives

• The filing does not provide new financial performance data or strategic updates for Forte Biosciences, Inc.

Risks

• The filing does not explicitly mention any new risks or challenges for Forte Biosciences, Inc.

Future Outlook

No forward-looking statements or specific future guidance are provided in this administrative filing.

Management Comments

• Each of the members of the management committee (Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu) disclaims beneficial ownership of the shares of Common Stock reported herein, except to the extent of their pecuniary interest therein.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like OrbiMed when their beneficial ownership of a public company's stock crosses certain thresholds. This filing reflects ongoing portfolio management activities within the biotechnology and healthcare investment sector.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant beneficial ownership, which is important for understanding the shareholder base.
• Management: The filing confirms that the ownership is not for the purpose of influencing control, providing clarity to the issuer's management.

Next Steps

• The OrbiMed entities will continue to hold and manage their beneficial ownership of Forte Biosciences, Inc. common stock.
• Future amendments to Schedule 13G will be filed if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, OrbiMed, Forte Biosciences, Amendment, Investment Management, Healthcare Investment